NEW YORK (GenomeWeb) – Becton Dickinson announced today that it has signed a development and global distribution agreement with Euroclone for molecular tests to detect emerging sexually transmitted diseases.

The molecular assays in development will provide an increased likelihood of patients receiving proper diagnoses and therapy whether or not they exhibit symptoms. The assays will also bolster antimicrobial stewardship in clinical laboratories and help institutions comply with European STI screening guidelines.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.